VBI Vaccines, Inc. is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials.

The company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets.

Employee Rating

0More
TypePublic
HQCambridge, US
Founded2001
Size (employees)98 (est)+12%
Websitevbivaccines.com
VBI Vaccines was founded in 2001 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

VBI Vaccines Office Locations

VBI Vaccines has offices in Cambridge, Rehovot and Ottawa
Cambridge, (HQ)
2241 222 Third St
Ottawa,
201 310 Hunt Club Rd
Rehovot,
Derech Gad Feinstein
Show all (3)
Report incorrect company information

VBI Vaccines Financials and Metrics

VBI Vaccines Revenue

VBI Vaccines 's revenue was reported to be $865 k in FY, 2017
USD

Revenue (Q3, 2018)

259.0k

Gross profit (Q3, 2018)

(542.0k)

Gross profit margin (Q3, 2018), %

(209.3%)

Net income (Q3, 2018)

(15.4m)

EBIT (Q3, 2018)

(14.5m)

Market capitalization (4-Dec-2018)

101.7m

Closing stock price (4-Dec-2018)

1.6

Cash (30-Sep-2018)

26.0m
VBI Vaccines 's current market capitalization is $101.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

548.0k865.0k

Cost of goods sold

3.7m5.2m

Gross profit

(3.1m)(4.3m)

Gross profit Margin, %

(570%)(500%)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

127.0k344.0k193.0k178.0k234.0k259.0k

Cost of goods sold

1.3m1.4m1.3m1.4m1.1m801.0k

Gross profit

(1.1m)(1.0m)(1.1m)(1.2m)(833.0k)(542.0k)

Gross profit Margin, %

(904%)(294%)(591%)(694%)(356%)(209%)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

6.7m12.6m32.3m67.7m

Accounts Receivable

10.0k143.0k

Inventories

830.0k788.0k

Current Assets

34.4m70.4m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

23.5m15.6m10.1m58.1m41.1m26.0m

Accounts Receivable

43.0k226.0k203.0k167.0k172.0k124.0k

Inventories

959.0k895.0k701.0k783.0k1.0m1.1m

Current Assets

25.8m18.8m13.0m60.4m44.9m30.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(1.5m)(14.4m)(13.9m)(23.2m)(39.0m)

Depreciation and Amortization

18.9k606.0k730.0k

Inventories

(93.0k)(89.0k)

Accounts Payable

11.0k(675.0k)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(8.6m)(17.7m)(27.5m)(12.3m)(29.0m)(44.3m)

Depreciation and Amortization

171.0k353.0k539.0k149.0k288.0k417.0k

Inventories

(78.0k)17.0k198.0k(286.0k)(373.0k)

Accounts Payable

(609.0k)49.0k614.0k946.0k1.3m
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

VBI Vaccines Online and Social Media Presence

Embed Graph
Report incorrect company information

VBI Vaccines News and Updates

VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)

CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that initial clinical data from the Phase 1/2a study of VBI-1901 in…

VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards

CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of three Scientific and Clinical Advisory Boards (SA…

VBI Vaccines Responds to Unfounded Allegations in Globes Article

CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12, 2018, written by Gali Weinreb (the “Article”) alleging that VBI failed to meet its responsibilities …
Report incorrect company information

VBI Vaccines Company Life and Culture

Report incorrect company information

VBI Vaccines Frequently Asked Questions

  • When was VBI Vaccines founded?

    VBI Vaccines was founded in 2001.

  • How many employees does VBI Vaccines have?

    VBI Vaccines has 98 employees.

  • What is VBI Vaccines revenue?

    Latest VBI Vaccines annual revenue is $865 k.

  • What is VBI Vaccines revenue per employee?

    Latest VBI Vaccines revenue per employee is $8.8 k.

  • Who are VBI Vaccines competitors?

    Competitors of VBI Vaccines include Alnylam Pharmaceuticals, Sorrento Therapeutics and Pernix Therapeutics.

  • Where is VBI Vaccines headquarters?

    VBI Vaccines headquarters is located at 2241 222 Third St, Cambridge.

  • Where are VBI Vaccines offices?

    VBI Vaccines has offices in Cambridge, Rehovot and Ottawa.

  • How many offices does VBI Vaccines have?

    VBI Vaccines has 3 offices.